(Q64876832)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:4750920%20AND%20SRC:MED&resulttype=core&format=json

4 October 2019

title

Effect of amantadine on L-2-14C-dopa metabolism in parkinsonism (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:4750920%20AND%20SRC:MED&resulttype=core&format=json

4 October 2019

main subject

parkinsonian syndrome

1 reference

M. J. Peaston

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A4750920

1 March 2023

J. R. Bianchine

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A4750920

1 March 2023

F. S. Messiha

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A4750920

1 March 2023

language of work or name

English

0 references

publication date

1 August 1973

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:4750920%20AND%20SRC:MED&resulttype=core&format=json

4 October 2019

16 August 1973

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=4750920

full work available at URL

1 March 2023

https://api.elsevier.com/content/article/PII:0024320573900222?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

https://api.elsevier.com/content/article/PII:0024320573900222?httpAccept=text/plain

1 March 2023

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

1 March 2023

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:4750920%20AND%20SRC:MED&resulttype=core&format=json

4 October 2019

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:4750920%20AND%20SRC:MED&resulttype=core&format=json

4 October 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:4750920%20AND%20SRC:MED&resulttype=core&format=json

4 October 2019

page(s)

237-246

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:4750920%20AND%20SRC:MED&resulttype=core&format=json

Amantadine in the Treatment of Parkinson's Disease

4 October 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Use of Amantadine in Parkinson's Disease. Results of a Double-blind Trial

1 March 2023

2

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Amantadine versus L-2 dopa and amatadine plus L-dopa.

1 March 2023

3

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Amantadine for Parkinson's disease.

1 March 2023

4

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

The effect of amantadine in parkinsonism: clinical and neurophysiological findings

1 March 2023

5

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Combined treatment of parkinsonism with L-dopa and amantadine

1 March 2023

6

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Controlled trial of amantadine hydrochloride in Parkinson's disease.

1 March 2023

7

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

[The treatment of parkinsonism with amantadine]

1 March 2023

8

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Amantadine and levodopa in the treatment of Parkinson's disease

1 March 2023

11

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Combined treatment of parkinsonism with L-dopa and amantadine

1 March 2023

14

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action

1 March 2023

16

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment.

1 March 2023

17

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Effects of amantadine and of some synthetic antiparkinsonian drugs on the behavioral response to L-DOPA in mice

1 March 2023

18

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

1 March 2023

19

13

202

Thornburg

1971

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Journal of Pharmacology and Experimental Therapeutics

1 March 2023

20

161

14

Bartholini

1968

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates.

1 March 2023

22

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

On the mode of action of amantadine.

1 March 2023

23

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Amantadine and catecholamine uptake

1 March 2023

24

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Evaluation of amantadine as a releasing agent or uptake blocker for H3-dopamine in rat brain slices

1 March 2023

25

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Effects of amantadine hydrochloride on catecholamine metabolism in the brain of the rat.

1 March 2023

26

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease

1 March 2023

27

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Amantadine-Dopamine Interaction: Possible Mode of Action in Parkinsonism

1 March 2023

28

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Dopamine: Release from the Brain in vivo by Amantadine

1 March 2023

29

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Treatment of Parkinson's disease with amantadine and levodopa. A one-year study

1 March 2023

30

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Concentrations of 5-hydroxyindolylacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with probenecid.

1 March 2023

32

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

Journal of Pharmacology and Experimental Therapeutics

1 March 2023

33

158

214

Neff

1967

1 reference

https://api.crossref.org/works/10.1016/0024-3205(73)90022-2

1 March 2023

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:4750920%20AND%20SRC:MED&resulttype=core&format=json

4 October 2019

1 reference